New thrombolytic, Retavase (reteplase)

    Boehringer Mannheim will market a new thrombolytic, Retavase (reteplase) dissolve blood clots and restore blood flow after a heart attack. It'll be out first in the U.S...later in Canada.

    Retavase is a derivative of tissue plasminogen activator (tPA)...the protein in Activase (alteplase).

    Retavase restores blood flow in more patients after 90 minutes than Activase. But so far there's no evidence of improved survival over Activase or streptokinase.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote